Allergan Total Assets 2006-2018 | AGN

Allergan total assets from 2006 to 2018. Total assets can be defined as the sum of all assets on a company's balance sheet.
  • Allergan total assets for the quarter ending September 30, 2018 were $106.543B, a 10.46% decline year-over-year.
  • Allergan total assets for 2017 were $118.342B, a 8.25% decline from 2016.
  • Allergan total assets for 2016 were $128.986B, a 4.87% decline from 2015.
  • Allergan total assets for 2015 were $135.583B, a 156.99% increase from 2014.
Allergan Annual Total Assets
(Millions of US $)
2017 $118,342
2016 $128,986
2015 $135,583
2014 $52,758
2013 $22,726
2012 $14,115
2011 $6,698
2010 $5,687
2009 $5,904
2008 $3,678
2007 $3,472
2006 $3,761
2005 $3,077
Allergan Quarterly Total Assets
(Millions of US $)
Q3 2018 $106,543
Q2 2018 $108,859
Q1 2018 $112,021
Q4 2017 $118,342
Q3 2017 $118,993
Q2 2017 $124,735
Q1 2017 $126,837
Q4 2016 $128,986
Q3 2016 $143,608
Q2 2016 $132,619
Q1 2016 $136,074
Q4 2015 $135,583
Q3 2015 $142,816
Q2 2015 $138,411
Q1 2015 $139,461
Q4 2014 $52,758
Q3 2014 $53,467
Q2 2014 $25,789
Q1 2014 $22,404
Q4 2013 $22,726
Q3 2013 $13,644
Q2 2013 $13,561
Q1 2013 $14,173
Q4 2012 $14,115
Q3 2012 $6,566
Q2 2012 $6,527
Q1 2012 $6,863
Q4 2011 $6,698
Q3 2011 $6,364
Q2 2011 $6,640
Q1 2011 $5,929
Q4 2010 $5,687
Q3 2010 $5,848
Q2 2010 $5,713
Q1 2010 $5,890
Q4 2009 $5,904
Q3 2009 $4,026
Q2 2009 $3,850
Q1 2009 $3,751
Q4 2008 $3,678
Q3 2008 $3,545
Q2 2008 $3,490
Q1 2008 $3,440
Q4 2007 $3,472
Q3 2007 $3,455
Q2 2007 $3,489
Q1 2007 $3,546
Q4 2006 $3,761
Q3 2006 $3,199
Q2 2006 $3,191
Q1 2006 $3,157
Q4 2005 $3,077
Q3 2005 $3,070
Q2 2005 $3,125
Q1 2005 $3,198
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $50.883B $15.941B
Allergan, Inc. is a healthcare company. It focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets. Allergan plc, formerly known as Actavis plc, is headquartered in Dublin, Ireland.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $19.341B 5.93
Mylan (MYL) United Kingdom $15.490B 6.38
Bausch Health Cos (BHC) Canada $8.272B 5.99
Dr Reddy's Laboratories (RDY) India $6.077B 24.24
Supernus Pharmaceuticals (SUPN) United States $1.860B 17.62
Mallinckrodt Public Limited Company (MNK) United Kingdom $1.735B 2.89
Amphastar Pharmaceuticals (AMPH) United States $0.963B 104.50
Homology Medicines (FIXX) United States $0.897B 0.00
Assembly Biosciences (ASMB) United States $0.579B 0.00
Akorn (AKRX) United States $0.567B 0.00
CymaBay Therapeutics (CBAY) United States $0.514B 0.00
Progenics Pharmaceuticals (PGNX) United States $0.397B 0.00
Voyager Therapeutics (VYGR) United States $0.343B 0.00
Adamas Pharmaceuticals (ADMS) United States $0.259B 0.00
Sol-Gel Technologies (SLGL) Israel $0.112B 0.00
Teligent (TLGT) United States $0.090B 0.00
Zynerba Pharmaceuticals (ZYNE) United States $0.077B 0.00
Aevi Genomic Medicine (GNMX) United States $0.076B 0.00
Aquinox Pharmaceuticals (AQXP) Canada $0.053B 0.00
Acasti Pharma (ACST) Canada $0.052B 0.00
Evoke Pharma (EVOK) United States $0.044B 0.00
Agile Therapeutics (AGRX) United States $0.028B 0.00
China Pharma Holdings (CPHI) China $0.011B 0.00
Pernix Therapeutics Holdings (PTX) United States $0.006B 0.00